Experimental Alzheimer’s Drug ACI-193 Passes Safety Testing and Advances to Larger Trials, Shows Promising Results in Targeting Toxic Protein Component beta-amyloid
Acumen Pharmaceuticals announced that an experimental Alzheimer’s drug developed by the company has passed preliminary safety testing and will move into larger trials. This drug targets a new form of the toxic protein component beta-amyloid in the brain. The company said the drug, ACI-193, was well received in its first trial in patients. The company … Read more